On August 28, 2026, a federal court in California entered a permanent injunction against California Stem Cell Treatment Center, Inc. and Cell Surgical Network Corporation over a stromal vascular fraction product made from patients’ own fat. This stem cell clinic injunction closed a case the Ninth Circuit decided in 2024. This post explains what the court ordered, how the case got there, and why a fat-derived SVF product differs from banked adipose tissue.
TLDR The August 2026 order declares the network’s SVF products to be drugs and bars the defendants from making or distributing them without an approved application, an IND, or a BLA. The case turned on minimal manipulation and the same surgical procedure exception. The order approves no product and says nothing about tissue banking. Banking adipose tissue does not guarantee any future use, which depends on FDA regulatory status at that time.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease or condition. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
Whether stem cell therapy is legal, and where, is the question readers bring to this site more than any other. The August 2026 order in United States v. California Stem Cell Treatment Center, Inc. answers it for one product category, fat-derived SVF, in one federal district. It also raises a follow-up for anyone who has banked fat: does a ruling against SVF say anything about intact tissue in storage?
The short answer is that the order concerns a product made from fat and implanted in patients, not intact fat tissue preserved for potential future use. Those are different activities under 21 CFR Part 1271. Nothing here is legal advice, and nothing here means banked tissue will ever have an approved use.
What the Stem Cell Clinic Injunction Ordered in August 2026
The court declared the defendants’ SVF products to be drugs and barred the defendants from making or distributing them without FDA authorization. The permanent injunction order, filed August 28, 2026 as Document 249 in the Central District of California, Eastern Division, names California Stem Cell Treatment Center, Inc., Cell Surgical Network Corporation, and one individual defendant.
The order defines “CSCTC products” as products the defendants prepare that contain stromal vascular fraction, or cells obtained or derived from adipose tissue, including expanded SVF products. It states that these products do not meet all of the criteria in 21 CFR 1271.10(a), that no exception in 21 CFR 1271.15 applies, and that they are drugs under 21 U.S.C. 321(g)(1).
Within 60 days the defendants must submit an investigational new drug application for each product, and they must stop if FDA imposes a clinical hold. Otherwise they may not receive, manufacture, process, pack, label, or distribute any CSCTC product that is not the subject of an approved new drug application, an IND, or a biologics license application. FDA may order cessation or recall and may inspect without notice at the defendants’ expense.
How the Case Reached a Permanent Injunction
The injunction follows a 2024 appellate decision. In No. 22-56014, decided September 27, 2024, the Ninth Circuit opinion held that the SVF product is a drug and that the same surgical procedure exception in 21 CFR 1271.15(b) does not apply. The key sentence is short: “Because the SVF procedure removes fat tissue but implants SVF, the procedure is not exempt from regulation under the SSP exception.”
The defendants petitioned for certiorari on May 19, 2025. The Supreme Court docket for No. 24-1189 records that the petition was denied on October 14, 2025, leaving the holding in place.
The Two Rules the Court Applied
The court applied the four criteria in section 1271.10(a) and the same surgical procedure exception in section 1271.15(b).
The four criteria must all be met at once: minimal manipulation, homologous use, no combination with another article beyond water, crystalloids, or a sterilizing, preserving, or storage agent, and a fourth criterion about systemic effect and living cells that carries a carve-out for autologous use.
For cells or nonstructural tissues, section 1271.3 defines minimal manipulation as processing that does not alter the relevant biological characteristics of the cells or tissues. This site has a plain-language walkthrough of what minimally manipulated means in practice.
The same surgical procedure exception is one sentence: an establishment need not comply with Part 1271 if it removes HCT/Ps from an individual and implants them into the same individual during the same surgical procedure. The exception text sets no time limit and does not use the word “fat.”
Why SVF Is Different From Banked Adipose Tissue
SVF and banked adipose tissue differ in what is done to the tissue, in whether anything is given to a patient, and in what a court has decided about each. Preserving intact adipose tissue is storage of the patient’s own tissue. It is not a treatment, and nothing is administered to anyone.
The table below puts the two side by side using only what the court documents and the regulation say.
| Question | SVF product in the case | Intact adipose tissue in storage |
|---|---|---|
| What is done to the tissue | Fat is removed and a product containing SVF or cells derived from the fat is prepared | Tissue is removed and preserved for potential future use; nothing is administered |
| Is it a treatment | Yes; the products were implanted in patients, and the court held they are drugs | No; storage does not connect the patient to any treatment pathway |
| What the court decided | Not all four 1271.10(a) criteria met, no 1271.15 exception, drugs | Nothing; the order does not mention banking |
| Future use | Only under an approved application, an IND, or a BLA | Depends on FDA regulatory status, physician guidance, and available pathways at that time |
The table is not a claim that banking is lawful in every setting or that stored tissue will ever qualify for anything. The question the court answered is not the question banking raises.
What the Ruling Does Not Decide
The ruling does not approve any product, does not address tissue banking, and does not reach beyond the parties and products before the court. A reader who skips those limits will misread this stem cell clinic injunction.
It does not approve anything. Nothing in the order says the products work or are safe; it says what the defendants must file and what they may not do.
It does not address banking. The order says nothing about intact adipose tissue in storage or what a stored sample could be used for later. This site’s comparison of banking versus clinics covers the practical differences.
It is one case. The injunction binds the named defendants. Other enforcement tools, including FDA warning letters, turn on their own facts, and nothing in the order changes the text of Part 1271.
What a Patient Can Take From the Ruling
A patient can take three lessons from the ruling: verify claims, read the FDA framework, and ask direct questions before paying for anything.
Verify claims against the record. If a clinic says its product is exempt from FDA oversight, ask which criterion in section 1271.10(a) or which exception in section 1271.15 it relies on, in writing.
Read the framework, not the marketing. Part 1271 defines an HCT/P as human cells or tissues intended for implantation, transplantation, infusion, or transfer into a human recipient. Advertising claims are policed separately, as this site’s review of the FTC enforcement pattern describes.
Ask a bank direct questions. This post says nothing about any laboratory’s registration, methods, or facilities; those facts must come from the bank itself. Ask whether it is registered with FDA, what is done to the tissue, and what the storage agreement says about future use.
Frequently Asked Questions
Does the injunction mean fat-derived stem cell products are illegal everywhere?
No. The order binds the named defendants and covers the CSCTC products as defined in the order. Whether any other product meets the four criteria is answered on the facts of that product.
Does banking fat give me access to SVF or a similar product later?
No. Banking preserves your own tissue. It does not connect you to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and available pathways at that time. The stem cell clinic injunction does not change that and creates no pathway.
Key Takeaways
The August 28, 2026 permanent injunction declares the defendants’ fat-derived SVF products to be drugs and bars them from making or distributing those products without an approved application, an IND, or a BLA. It follows the Ninth Circuit’s 2024 holding that SVF is a drug and the same surgical procedure exception does not apply. The case concerns a product made from fat and implanted in patients. It does not address intact adipose tissue in storage, approves nothing, and changes nothing in Part 1271. Banking preserves tissue for potential future use and guarantees nothing about that use, which depends on FDA status at that time.
Save My Fat connects patients and providers with a U.S.-based tissue bank. It is not a tissue bank, a laboratory, a medical practice, or a treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, California, Georgia, and Tennessee governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Readers weighing adipose tissue banking for potential future use can review current pricing or ask a question through the contact page.
Save My Fat works with a U.S.-based tissue bank for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Please consult your own licensed healthcare provider before making any decisions about treatment or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: FDA adipose tissue regulation.
